Literature DB >> 9542645

B-lymphoblastoid cell lines from cancer patients.

W K Lee, S M Kim, Y S Sim, S G Cho, S H Park, C W Kim, J G Park.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9542645     DOI： 10.1007/s11626-998-0090-1

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN： 1071-2690            Impact factor:   2.416


× No keyword cloud information.
  11 in total

1.  The role of repetitive DNA sequences in the size variation of Epstein-Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis.

Authors:  K Falk; J W Gratama; M Rowe; J Z Zou; F Khanim; L S Young; M A Oosterveer; I Ernberg
Journal:  J Gen Virol       Date:  1995-04       Impact factor: 3.891

2.  Persisting oncogenic herpesvirus induced by the tumour promotor TPA.

Authors:  H zur Hausen; F J O'Neill; U K Freese; E Hecker
Journal:  Nature       Date:  1978-03-23       Impact factor: 49.962

3.  Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins.

Authors:  M Rowe; L S Young; K Cadwallader; L Petti; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

4.  Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

5.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.

Authors:  J Sample; L Young; B Martin; T Chatman; E Kieff; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

6.  Subnuclear localization and phosphorylation of Epstein-Barr virus latent infection nuclear proteins.

Authors:  L Petti; C Sample; E Kieff
Journal:  Virology       Date:  1990-06       Impact factor: 3.616

7.  Characterization of cell lines established from human hepatocellular carcinoma.

Authors:  J G Park; J H Lee; M S Kang; K J Park; Y M Jeon; H J Lee; H S Kwon; H S Park; K S Yeo; K U Lee
Journal:  Int J Cancer       Date:  1995-07-28       Impact factor: 7.396

Review 8.  Epstein-Barr virus-associated lymphoproliferative disorders.

Authors:  D T Purtilo; R S Strobach; M Okano; J R Davis
Journal:  Lab Invest       Date:  1992-07       Impact factor: 5.662

9.  Expression of integrins and other adhesion molecules in Epstein-Barr virus-transformed B lymphoblastoid cells and Burkitt's lymphoma cells.

Authors:  J Rincon; J Prieto; M Patarroyo
Journal:  Int J Cancer       Date:  1992-05-28       Impact factor: 7.396

Review 10.  Epstein-Barr virus immortalizing genes.

Authors:  P J Farrell
Journal:  Trends Microbiol       Date:  1995-03       Impact factor: 17.079
View more
  5 in total

1.  The role of promoter methylation in Epstein-Barr virus (EBV) microRNA expression in EBV-infected B cell lines.

Authors:  Do Nyun Kim; Yoon Jae Song; Suk Kyeong Lee
Journal:  Exp Mol Med       Date:  2011-07-30       Impact factor: 8.718

2.  Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome.

Authors:  Eun Kyung Lee; Sun Young Kim; Ka-Won Noh; Eun Hye Joo; Bo Zhao; Elliott Kieff; Myung-Soo Kang
Journal:  Antiviral Res       Date:  2014-01-31       Impact factor: 5.970

3.  An Epstein-Barr virus isolated from a lymphoblastoid cell line has a 16-kilobase-pair deletion which includes gp350 and the Epstein-Barr virus nuclear antigen 3A.

Authors:  W Lee; Y H Hwang; S K Lee; C Subramanian; E S Robertson
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

5.  High prevalence of the EBER variant EB-8m in endemic nasopharyngeal carcinomas.

Authors:  Zhi-chao Shen; Bing Luo; Jian-ning Chen; Yan Chao; Chun-kui Shao; Qian-qian Liu; Yun Wang
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.